DNTH - NASDAQ

Dianthus Therapeutics, Inc.

DNTH·NASDAQ

$84.13

+0.88%

HealthcareBiotechnology

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$3.51B

EPS-4.2000

P/E Ratio-20.03

Earnings Date08/06/2026

dnth

Net Cash Provided by Financing Activities

Last Annual Value

280.12M

3-Year CAGR

43%

5-Year CAGR

33%

10-Year CAGR

39%

Adjust for Inflation

Dianthus Therapeutics, Inc. Competitors Analysis of Net Cash Provided by Financing Activities

DNTH · NASDAQ

Company	Net Cash Provided by Financing Activities	CAGR 3Y	CAGR 5Y	CAGR 10Y
Dianthus Therapeutics, Inc. NASDAQ:DNTH	280.12M	28.0%	25.6%	38.6%
BridgeBio Oncology Therapeutics Inc. NASDAQ:BBOT	383.40M	N/A	N/A	N/A
AnaptysBio, Inc. NASDAQ:ANAB	-132.61M	N/A	N/A	N/A
Nektar Therapeutics NASDAQ:NKTR	180.57M	1719.0%	37.9%	-1.2%
Enliven Therapeutics, Inc. NASDAQ:ELVN	218.87M	-2.2%	N/A	N/A
Sana Biotechnology, Inc. NASDAQ:SANA	128.73M	59.6%	-27.3%	N/A
Tourmaline Bio, Inc. NASDAQ:TRML	161.35M	1.0%	3.3%	N/A
Taysha Gene Therapies, Inc. NASDAQ:TSHA	274.59M	26.3%	47.7%	N/A
Atai Beckley Inc. NASDAQ:ATAI	269.48M	N/A	-8.0%	N/A

Dianthus Therapeutics, Inc. Fair Value Envelope

DNTH · NASDAQ

Our analysis suggests that DNTH has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $84.13, this represents a potential HIDDEN relative to our calculated worth for Dianthus Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $84.13

Related Guides

Blog Categories

Continue your DNTH research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.